Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Open in API
Filings indexed 208 across all filing types
Latest filing 2024-08-07 Regulatory Filings
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
Form of proxy - English.pdf
Regulatory Filings
2024-08-07 English
News release - English.pdf
Regulatory Filings
2024-07-18 English
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings Classification · 95% confidence The document is a confirmation notice from TSX Trust Company regarding the record and meeting dates for an upcoming Annual and Special Meeting of Security Holders for Thiogenesis Therapeutics Corp. It includes details such as the meeting date, record date, classes of securities entitled to vote, and proxy-related material delivery information. The document does not contain any financial data, management discussion, or detailed report content. It is a notification about the scheduling and logistics of a shareholder meeting rather than the meeting materials or results themselves. Given the short length (1868 characters) and the nature of the content, this fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than a full report or presentation.
2024-06-25 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a confirmation notice from TSX Trust Company regarding the record and meeting dates for an upcoming Annual Meeting of Security Holders for Thiogenesis Therapeutics Corp. It specifies the meeting date, record date, classes of securities entitled to vote, and proxy-related material delivery details. The document does not contain any financial data, management discussion, or detailed report content. It is a formal announcement related to the scheduling and logistics of the annual meeting rather than the meeting materials or results themselves. Given the short length (1816 characters) and the nature of the content, this fits the category of a Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Regulatory Filing (RNS). However, since it is about confirming notice of record and meeting dates (pre-meeting information), it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about meeting logistics rather than voting results or proxy solicitation materials.
2024-06-25 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for the three months ended March 31, 2024 and 2023, indicating it is a quarterly or interim financial report. It contains detailed financial statements including statements of financial position, operations, changes in equity, and cash flows, along with notes explaining accounting policies and estimates. The document references compliance with IAS 34 'Interim Financial Reporting' and IFRS standards, which are typical for interim reports. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-05-24 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis For the Three Months Ended March 31, 2024' and contains detailed discussion of the company's business, clinical trials, regulatory plans, and financial performance for the quarter. It references unaudited condensed interim consolidated financial statements for the three months ended March 31, 2024, prepared under IAS 34 Interim Financial Reporting. The content includes financial results, operational updates, and forward-looking statements typical of an interim or quarterly report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-05-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.